Avanos Medical Presents New Preclinical Data Comparing the Outcomes of COOLIEF* Cooled Radiofrequency to Standard RF
Data from Avanos Medical offers guidance to understanding long-term pain relief seen in cooled radiofrequency versus standard techniques.

ALPHARETTA, Ga., Nov. 16, 2018 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) presented new scientific research supporting the long-term effects seen in COOLIEF* Cooled Radiofrequency (RF) for the management of chronic pain at the 17th Annual American Society of Regional Anesthesia and Pain Medicine (ASRA) meeting.

The Cooled RF Authority

The new preclinical data evaluated the physiological outcomes of Cooled Radiofrequency as a novel technique compared to traditional techniques in a clinically relevant animal model. The study showed Cooled RF generated more than three and a half times as much energy and created larger lesions which took longer to resolve. Additionally, the study outcomes showed Cooled RF produces enhanced thermal lesions and has greater duration of effect than the comparator. 

"In our hands, the Cooled RF treatments produced a far stronger, far more consistent, and longer-lasting effect on nerve conduction than Standard RF treatments," said Arthur English, PhD, lead study investigator and Professor of Cell Biology at Emory University.

David Curd, Vice President Clinical Affairs and Professional Education at Avanos said, "This study provides significant new scientific data to support the growing body of COOLIEF* Cooled RF clinical evidence of up to 24 months of pain relief for patients who suffer from chronic pain and the recommendation of 91 percent of the surveyed physicians who use it."

For more information about COOLIEF* Cooled Radiofrequency for the management of chronic pain, visit avanospainmanagement.com.

About Avanos Medical, Inc.
Avanos Medical, Inc. (NYSE: AVNS) is a medical technology company focused on delivering clinically superior breakthrough medical device solutions to improve patients' quality of life. Headquartered in Alpharetta, Georgia, Avanos is committed to addressing some of today's most important healthcare needs, such as reducing the use of opioids while helping patients move from surgery to recovery. Avanos develops, manufactures and markets its recognized brands in more than 90 countries. For more information, visit avanos.com.

SOURCE Avanos Medical, Inc.

For further information: Investor Contact: Dave Crawford, Avanos Medical, Inc., 470-448-5177, Investor.Relations@Avanos.com; Media Contact: Caitlin Vaiskauskas, Edelman, (404) 457-5849,Caitlin.Vaiskauskas@edelman.com